0

patients benefit in clinical trial

0

Million $ outlicensing deal

Approach:

A end-to-end pipeline identifying possible epitopes from patient’s tumor data was designed and implemented.

Performance:

Clinical responses were observed after treatment start in 50% of all analysed patients across tumor types.

Outcome:

Vaccibody got a high-performance neoepitope pipeline that has become an integral part of their successful vaccine-based treatment, which was later out-licensed in a $700+ M deal with Genentech